Introduction
The technique of radioimmunolocalization (RIL) of organs using antibodies was pioneered by Pressman & Keighley in 1948 . During the 1970s this was developed, using affinity purified heteroantisera particularly to tumour-associated antigens such as carcinoembryonic antigen (CEA) and alphafetoprotein (AFP). Antisera were radiolabelled with 131-I and preliminary work was undertaken in animal models. Studies in patients were first reported by Goldenberg et al. in 1978 using heteroantisera to CEA to image gastrointestinal, ovarian and cervical tumours. This has been extended, using a range of heteroantisera, to include testicular (Goldenberg et al. 1981) , prostate (Goldenberg et al. 1983 ) and renal malignancies (Belitsky et al. 1978 ) and choriocarcinomas (Begent et al. 1980) . The development of monoclonal antibody technology has made it possible to obtain virtually unlimited quantities of pure reagents (Kohler & Milstein 1975) . Their potential for RIL has been explored both in animal models and patients, with a constantly increasing range of tumours (Mach et al. 1981 , Epenetos et al. 1982 , Berche et al. 1982 .
Tumours of neural origin have not featured widely in radioimmunolocalization studies. Monoclonal antibodies to melanoma have been used to localize tumours in patients (Larson et al. 1983) . In children, using the monoclonal antibody UJ13A, primary and secondary tumours have been detected by RIL (Goldman et al. 1984) . Early attempts to image gliomas using heteroantisera labelled with 125-I were reported by Mahaley in 1968 . Phillips et al. (1982 have recently demonstrated localization of a human monoclonal antibody in one patient with a recurrent glioma. It is pertinent to question why little work has been undertaken on the RIL of intracranial malignancies. This may be because of the reluctance to use antibodies which cross-react with normal neural tissue and/or the uncertainty as to whether the blood-brain barrier will allow access of the antibody to the tumour. Monoclonal antibodies are already proving to be valuable new tools in the in vitro diagnosis of tumours (Kemshead et al. 1983b) . In this paper the possibility that they also may have either an in vivo diagnostic or therapeutic role will be discussed.
Monoclonal antibodies
The ideal monoclonal antibody for radioimmunolocalization of brain tumours is one which binds only to malignant cells. Unfortunately such reagents do not exist. Claims of this degree of specificity are not substantiated by a review of the literature on monoclonal antibodies against any tumour cell type (Pallensen et al. 1983 , Braun et al. 1983 , Shnegg et al. 1981 . However, the concept of 'operational specificity' appears to be becoming increasingly important and antibodies can be used successfully for a variety of in vivo and in 'Paper read to Section of Neurology, 12 January 1984 . Accepted 11 April 1984 Journal of the Royal Society of Medicine Volume 77 October 1984 vitro diagnostic and therapeutic procedures without exclusive tumour reactivity (Treleaven et al. 1984 , Miller et al. 1982 , Greaves et al. 1978 , Ritz et al. 1982 . Candidate antibodies which may give sufficient specificity for radioimmunolocalization of brain tumours certainly exist (Kemshead & Coakham 1983) . These can be divided into several classes according to the selective nature of their reactivity (Kemshead 1984b) .
The most broadly reacting reagents are those which bind to either all or most neuroectodermally-derived tumours/tissues. An example of this type of antibody is UJ13A, made following immunization of mice with 16-week human fetal brain (Allan et al. 1983) . Indirect immunofluorescence studies of frozen sections of fetal, paediatric and adult tissues indicate that the only neuroectodermally-derived tissues/tumours which do not bind UJ13A are melanocytes and melanoma. UJ13A binds to both neural and glial cells in the brain. First considerations suggest that this type of reactivity is too broad to be useful for radioimmunolocalization studies.
Other antibodies with a more restricted pattern of binding to neural tissues and tumours also have been produced. UJ127.11 is a monoclonal antibody binding to neural rather than glial cells in brain (Kemshead et al. 1983a ). Studies of frozen sections of neuronal tumours indicate that the reagent binds to medulloblastomas and neuroblastomas but not to 7 of 7 gliomas tested. The antigen recognized by this monoclonal antibody is a 220-240 000 molecular weight glycoprotein found in the membrane of neural cells. Conversely, FD19.9 is a monoclonal antibody binding only to glial rather than neural cells and recognizes a 55 000 molecular weight intracellular antigen, glial fibrillary acidic protein (Eng et al. 1971 ). This reagent was raised following immunization of mice with a low grade astrocytoma (Kemshead et al., unpublished observation) . Monoclonal antibodies have been described with even greater specificity to cell types found in the brain. For example UCHT1, whilst binding a membrane antigen on T-lymphocytes, also cross-reacts with an intracellular antigen found only in Purkinje's cells (Garson et al. 1982 ). In addition, the hybridization that gave rise to FD19.9 also produced a reagent (FD54) that specifically binds to a band of cells found in the granular layer of the cerebellum (Kemshead et al., unpublished observation) . However all these antibodies, whilst sharing restricted specificity for different neuronal cell types, are not capable of distinguishing malignant cells from their normal counterparts.
A group of reagents which begin to satisfy this requirement are those with an 'oncofetal' type of specificity. These are antibodies binding to differentiation antigens expressed on fetal and malignant neuronal cells. They are lost as cells differentiate to a more mature cell type. Examples of antibodies with this type of specificity are UJ 181.4 (Kemshead 1984a ) and M340 (Kemshead et al., unpublished observation) made following immunization of mice with human fetal brain and fresh human medulloblastoma respectively. Both these reagents bind to frozen sections of fetal brain, medulloblastoma, neuroblastoma and retinoblastoma, but not to paediatric or adult brain as assessed by indirect immunofluorescence studies.
Finally, several antibodies have been produced which, on initial characterization, appeared to bind only to malignant cells and not to normal fetal or adult neuronal tissues. FD32.3, made by immunizing mice with low-grade human astrocytoma, was thought initially to bind to gliomas but not normal glial cells from fetal or adult brain (Kemshead et al., unpublished observation) . However, extensive characterization of the binding of this antibody showed that activated glial cells found at sites of inflammation also express the FD32.3 antigen. This antibody binds to an extracellular matrix protein found in gliomas, and other reagents with similar specificities have now been produced (Bouden et al. 1983 ). FD32.3 has also been found to bind to a series of non-neuroectodermally derived tumours, outside the brain, such as rhabdomyosarcoma and Ewing's tumours.
When establishing the precise specificities of monoclonal antibodies, they are often found to bind to completely unrelated tissues. FD32.3 demonstrates this, as does UCHT1 (Beverley & Callard, 1981) . The antibody A2B., thought to bind only to neural cells, has been shown to react with 26 of 40 adenocarcinomas (Coakham et al., unpublished observation) . Whether these rather unexpected cross-reactions are due to shared antigens Journal of the Royal Society of Medicine Volume 77 October 1984 849 between distinct cell types or to shared epitopes on biochemically dissimilar antigens remains to be determined in many cases (Kemshead et al. 1982) . Whatever the explanation for such cross-reactivities, the observation stresses the need for extensive studies on sections of tissues and tumours before reagents may be considered for radioimmunolocalization studies.
Blood-brain barrier Radioimmunolocalization studies on children with disseminated neuroblastoma reveal that the mouse IgG monoclonal antibody UJ1 3A does not cross the blood-brain barrier. Despite the antibodies binding to neural and glial cells in frozen sections of paediatric neural tissue, no uptake of the reagent is seen in the brain by radioimmunolocalization studies (Figure 1) . Similarly, UJ13A does not cross the retinal blood barrier (Figure 1 ). In the case illustrated, uptake of the antibody to a primary abdominal tumour was detected by gamma camera scan (data not shown). In addition, metastatic spread of neuroblastoma into the vault of the skull was detected, illustrating that the UJ1 3A conjugate has not lost its capability to bind antigen during the radiolabelling procedure ( Figure 1) .
Breakdown of the blood-brain barrier has therefore to occur for radiolabelled antibody to gain access to any tumours. This may occur to varying degrees in either the same or different tumour types (Vick & Bigner 1972) . Patients should therefore first receive a 99m-technetium scan as a prerequisite for attempting RIL of intracranial tumours. If this shows disruption of the blood-brain barrier, then it is possible to question whether tumour can be identified specifically with radiolabelled monoclonal antibody Radioimmunolocalization of brain tumours Despite the non-selective binding of UJ13A to normal and malignant intracranial tissues, this antibody was initially chosen to visualize tumours because of the experience gained in using it for radioimmunolocalization of neuroblastoma. In the first study 4 patients were scanned, 3 with gliomas and one with a meningioma. All patients had previously received a 99m-technetium scan demonstrating disruption of the blood-brain barrier. Informed consent as well as ethical committee approval was obtained for the study. Mouse monoclonal antibody UJ13A was purified by protein A chromatography, extensively dialysed against phosphate buffered saline (PBS) and frozen in aliquots at -70°C. Protein was radiolabelled~~~~~~~~~~~~~~~~~.
. . . . . . . l . . . . . . Figure 1 . Radioimmunolocalization of monoclonal antibody UJ 13A to neuroblastoma deposits in the vault of the skull. A nine-year-old girl with stage IV neuroblastoma was injected with 1.5 mCi of 123-I radiolabelled UJ1I3A (300 pg). Images of the tumour deposits in the vault of thfe skull (A) were obtained 2 days after administration of the conjugate. These correspond to abnormal sites on skull radiographs and 99m-technetium isotope bone scans. The intracranial area (B) and orbit show no uptake of the conjugate by the chloramine T technique and sterilized by passage through a 0.22 gm millipore filter (Goldman et al. 1984) . Patients received, by intravenous injection, 1.5-2.0 mCi of 131-I conjugated to approximately 250 jug of UJ13A.
Immediately after injection and 4 hours later no uptake of 131-I into the tumours could be detected in any patient. However, in all cases clear images of tumour could be identified at 24 hours, even without computer enhancement. These could still be identified 12-14 days after the initial scan. The kinetics of radiolabelled UJ13A association and dissociation from the tumour site are therefore grossly different from that of 99m-technetium scan where tumours can be imaged within 4 hours. Figure 2 illustrates anteroposterior and lateral images of a meningioma taken 24 hours after injection of 131-I conjugated UJ1 3A. The binding of the radiolabelled antibody is restricted to the tumour and possibly normal brain juxtaposing the malignant area. As might be suspected from data obtained by 99m-technetium scans, tumours do not cause generalized disruption of the blood-brain barrier. The 'operational specificity' of UJ13A is therefore maintained, as the reagent cannot reach areas of 'normal tissue' where binding could otherwise also occur.
Computer analysis of the amount of UJ13A/1 31-I conjugate in the tumour against that present in blood of normal brain indicates a ratio of at least 3: 1 six days following the initial injection. This ratio increases with respect to time as the radiolabel is lost from the blood at a faster rate than from the tumour (half-life in the blood approximately 24 hours as compared to 72 hours in the tumour). Direct counting of isotope in the tumour and normal brain at the time of operation approximately parallels the data obtained by computer analysis of gamma camera images, and indicates that the ratio of conjugate in tumour to normal brain can be as high as 16: 1, 16 days after injection of radiolabelled antibody.
Specificity of binding
Prior to the use of 99m-technetium for identifying brain tumours, radiolabelled albumin was used as an 'imaging' agent in nuclear medicine. As with technetium, this reagent was obviously used simply to identify areas of blood-brain barrier disruption. It is therefore essential to demonstrate that the UJ13A/131-I conjugate used is binding specifically to antigenic sites in the tumour and not also simply acting as another agent showing bloodbrain barrier disruption. The simplest approach to demonstrate that tumour uptake is specific to antigen is to repeat the procedure, with an alternative antibody, in a patient who has already received a UJ13A/131-I scan. The second series of images would follow injection of a radiolabelled antibody known not to bind to antigenic sites in the tumour. Whilst this is an ideal approach, it presents ethical problems both in terms of the doses of Nude mice were injected with either radiolabelled UJI3A or FD44 monoclonal antibodies. Five days later blood and major organs. were removed from the animals, weighed and radioisotope levels determined using a gamma counter. 0 Uptake of radioisotope per gram of tissue was estimated and the results expressed as a ratio of organ to blood level MOrgans examined liver, kidney, spleen, lung, adrenal, muscle, skin, and brain isotope given to the patient and unwarranted delays caused in treatment. It is proposed to attempt this study using 123-I rather than 131-I radiolabelled antibodies, as the former isotope has a half-life of only 13.3 hours. This means that by using 2 mCi of 123-I conjugated to UJ13A, it is possible to see images of neuroblastoma metastasis in children only up to 48 hours after injection of the conjugate (Goldman et al. 1984) . The procedures can be compacted and the total dose of ionizing radiation to the patient considerably reduced. However other technical problems can limit the feasibility of this approach to determining specificity of antibody binding (e.g. irreproducibility of radiolabelling protein with 123-I).
Two patients with malignant glioma have been injected with radiolabelled antibody known not to bind to tumour cells. The kinetics of the association and dissociation from the tumour parallel those for the conjugate in the blood. This is exactly the result one would expect from nonspecific entry of the 131-I conjugate into tumour sites because of bloodbrain barrier breakdown and the opposite of that expected in patients where an antibody known to bind to tumour is used. Unfortunately, because of the need for surgery, only 99mtechnetium scans were undertaken on these patients and therefore it was not possible to complete the study with UJ13A/131-I conjugates.
Using nude mice xenografted with human tumours, it has been possible to demonstrate specific UJ13A uptake into the graft. Mice with subcutaneous human neuroblastomas were injected with 15 ,Ci of radioiodine conjugated to 15 ug of UJ1 3A and sacrificed at varying times (1 to 10 days from receiving the conjugate). The amount of radiolabelled antibody in the tumour was compared on a weight-for-weight basis with that found in the blood. In a series of experiments tumour uptake was found to be 4-23 times that found in an equivalent weight of blood (Table 1) . No similar uptake was seen in any other organs of the mice. When a non-neuroblastoma binding antibody (FD44) was used for these studies, no tumour uptake was seen, as the tumour-to-blood ratio of radiolabel was always 1 or less than 1 (Table 1) .
Thus whilst there is no direct proof that the 131-I antibody conjugate binds specifically to antigen in tumours, all data currently obtained suggest that this is the case. Further studies are planned on a series of patients to prove this point conclusively.
Is radioimmunolocalization of brain tumours using radiolabelied monoclonal antibody an improvement over conventional procedures? Comparison of a 99m-technetium and a UJ13A/131-I antibody scan shows that tiere is no improvement in image using the latter reagent (Figure 3 ). However, this comparison is Figure 3 . Comparison of images of a brain tumour obtained by 99m-technetium and radiolabelled antibody. Images of an intracranial malignancy were obtained using 131-I radiolabelled UJ13A as described in Figure 2 . Images were obtained using a medium energy collimator. Prior to this scan the patient was given 20 mCi of 99mtechnetium. Images were obtained at 4 hours using a low energy collimator. (A, 99m-technetium scan. B, UJ 13A/1 3 1-I scan. T, tumour deposits) currently hardly justified as very limited experience has been obtained with radiolabelled antibody, and 131-I as an imaging agent is not ideal. It is possible that the use of indium-11l antibody conjugates will considerably improve the resolution of the isotope scans. However even with the use of more specific antibodies and more suitable isotopes for imaging, the scans will take longer to analyse than those with 99m-technetium (see above). It is unlikely that our ability to detect very small tumours will be enhanced by using targeted isotopes. This is because the antibody and 99m-technetium imaging procedures are totally dependent on blood-brain barrier disruption. The antibody isotope approach to imaging tumours may, however, be exploited to target therapeutic agents to intracranial malignancies.
Can monoclonal antibodies be used to target therapeutic agents to tumours? The concept of selectively targeting therapeutic agents to tumours, to reduce toxicity to normal tissues, has been in existence for many years. Monoclonal antibodies, with their high degree of actual or 'operational' specificity, are obvious candidates for targeting 'therapy' to tumours (Foon 1982) . The refractory nature of many intracranial malignancies, particularly grade IV astrocytomas, also makes these tumours candidates for new modes of therapy. Antibodies conjugated with drugs (Johnson et al. 1982) , toxins (Thorpe et al. 1982 ) and radioisotopes (Order et al. 1983 ) have been used to selectively kill tumour cells in vitro. It has proved more difficult to ablate tumours in vivo than initial studies indicated. However, this has been possible using nude mice xenografted with human neuroblastoma (Kemshead, unpublished observation) . Tumours of approximately 1.0 cm diameter can be ablated in animals given three injections of 150 4uCi of 131-I conjugated to 150 ,ug of UJ1 3A over a 23-
week period (Figure 4) . Other experiments have demonstrated this effect to be due to 131-I and not due to either the antibody alone or other isotopes of iodine. Presumably ,B irradiation from 131-I with a penetration of approximately 2.0 mm in human tissues is responsible for the cytotoxic effect of the conjugate. Mice cannot be used to estimate the toxicity of a UJ1 3A radiolabelled conjugate to normal tissues as the antibody does not bind to murine neural tissues. Furthermore, a mouse monoclonal antibody injected into a mouse will be recognized and processed by the reticuloendothelial system in a different way than if it were injected into a primate. High doses of UJ1 3A/1 31-I conjugates have therefore been injected into marmosets (4 x 2.0 mCi of 131-1 coupled to 2.0 mg of UJ1 3A) over a period of 12 months. Animals given this conjugate, and others given control injections of either 131-I alone or antibody alone, suffered no gross psychological or physiological disturbance. As was predicted from biodistribution studies of small doses of conjugate in patients with stage IV neuroblastoma, no 131-I was detected intracranially in the marmosets, although the adrenal medulla showed antibody uptake (Kemshead et al. 1985) . Thus whilst certain tissues, e.g. brain and retina, are protected from the high doses of isotope/antibody conjugate by blood-tissue barriers, others may suffer damage from the targeted agent.
A phase one study in children relapsing with stage IV neuroblastoma has begun to investigate toxicity of this type of targeted therapy. Extensive discussion of this data is beyond the scope of this paper, but preliminary data indicate that small tumour masses may be ablated by this form of therapy. Although no sizable toxicity problems have been encountered in the study, much work remains, particularly to reduce the uptake of the conjugate by the reticuloendothelial system. This approach to therapy of refractory brain tumours should not be overlooked and it is hoped that preliminary studies in this field will begin in the near future.
